Top

Published in:

01-07-2013 | Clinical Trial

Increased expression of Mitotic Arrest Deficient-Like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer

Authors: Qian Sun, Xianyu Zhang, Tong Liu, Xiaolong Liu, Jingshu Geng, Xiaohui He, Yang Liu, Da Pang

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

Aneuploidy is a characteristic of human cancers, and recent studies have suggested that defects of mitotic checkpoints play a role in carcinogenesis. Mitotic Arrest Deficient-Like 1 (MAD1L1), whose altered expression is associated with chromosomal instability, is a checkpoint gene. We examined MAD1L1 protein expression from 461 breast cancer tissues and patients’ normal breast tissues by tissue microarray to study the correlation between the MAD1L1 expression and the clinicopathological features. MAD1L1 protein expression was significantly increased in the nuclei of cancer cells (28.4 %) compared with that in normal mammary cells (2.2 %), and was correlated with Her-2 status, cancer subtypes, p53 status, and age. High level of MAD1L1 expression in nuclei was associated with worse OS (p = 0.018). Furthermore, patients with high level of MAD1L1 expression (in nuclei) and undergone Taxol chemotherapy treatment have shorter overall survival than ones without Taxol treatment in this study (p = 0.026). In conclusion, our data demonstrated a significant correlation between nuclear expression of MAD1L1 protein and adverse prognosis in breast cancer. MAD1L1 might be used as a prognostic biomarker for breast cancer and expression of MAD1L1 in nuclei is also a predict biomarker of contraindication to pacilitaxel treatment in breast cancer.

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138 PubMedCrossRef

Olopade OI, Grushko TA, Nanda R, Huo D (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14(24):7988–7999. doi:10.1158/1078-0432.CCR-08-1211 PubMedCrossRef

Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP (1998) Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosom Cancer 21(3):177–184PubMedCrossRef

Mendelin J, Grayson M, Wallis T, Visscher DW (1999) Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. Lab Investig 79(4):387–393PubMed

Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392(6673):300–303. doi:10.1038/32688 PubMedCrossRef

Pihan GA, Doxsey SJ (1999) The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol 9(4):289–302. doi:10.1006/scbi.1999.0131 PubMedCrossRef

Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H (1999) Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 18(30):4295–4300. doi:10.1038/sj.onc.1202807 PubMedCrossRef

Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8(5):379–393. doi:10.1038/nrm2163 PubMedCrossRef

Rieder CL (2011) Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints. Chromosom Res 19(3):291–306. doi:10.1007/s10577-010-9178-z CrossRef

10.

Li X, Nicklas RB (1995) Mitotic forces control a cell-cycle checkpoint. Nature 373(6515):630–632. doi:10.1038/373630a0 PubMedCrossRef

11.

Rieder CL, Cole RW, Khodjakov A, Sluder G (1995) The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores. J Cell Biol 130(4):941–948PubMedCrossRef

12.

Rieder CL, Schultz A, Cole R, Sluder G (1994) Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J Cell Biol 127(5):1301–1310PubMedCrossRef

13.

Amon A (1999) The spindle checkpoint. Curr Opin Genet Dev 9(1):69–75PubMedCrossRef

14.

Sanchez Y, Bachant J, Wang H, Hu F, Liu D, Tetzlaff M, Elledge SJ (1999) Control of the DNA damage checkpoint by chk1 and rad53 protein kinases through distinct mechanisms. Science 286(5442):1166–1171PubMedCrossRef

15.

Chen RH, Brady DM, Smith D, Murray AW, Hardwick KG (1999) The spindle checkpoint of budding yeast depends on a tight complex between the Mad1 and Mad2 proteins. Mol Biol Cell 10(8):2607–2618PubMedCrossRef

16.

Iouk T, Kerscher O, Scott RJ, Basrai MA, Wozniak RW (2002) The yeast nuclear pore complex functionally interacts with components of the spindle assembly checkpoint. J Cell Biol 159(5):807–819. doi:10.1083/jcb.200205068 PubMedCrossRef

17.

Campbell MS, Chan GK, Yen TJ (2001) Mitotic checkpoint proteins HsMAD1 and HsMAD2 are associated with nuclear pore complexes in interphase. J Cell Sci 114(Pt 5):953–963PubMed

18.

Howell BJ, McEwen BF, Canman JC, Hoffman DB, Farrar EM, Rieder CL, Salmon ED (2001) Cytoplasmic dynein/dynactin drives kinetochore protein transport to the spindle poles and has a role in mitotic spindle checkpoint inactivation. J Cell Biol 155(7):1159–1172. doi:10.1083/jcb.200105093 PubMedCrossRef

19.

Musacchio A (2011) Spindle assembly checkpoint: the third decade. Philos Trans R Soc Lond B 366(1584):3595–3604. doi:10.1098/rstb.2011.0072 CrossRef

20.

Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M, Sawyers C, Said JW, Koeffler HP (2001) Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene 20(25):3301–3305. doi:10.1038/sj.onc.1204421 PubMedCrossRef

21.

Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12(2):405–410. doi:10.1158/1078-0432.CCR-05-0903 PubMedCrossRef

22.

Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD, Yuh YJ, Kim SR, Suh HS (2000) Clinical implication of altered expression of Mad1 protein in human breast carcinoma. Cancer 88(7):1623–1632PubMedCrossRef

23.

Matkovic B, Juretic A, Separovic V, Novosel I, Separovic R, Gamulin M, Kruslin B (2008) Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori 94(6):838–844PubMed

24.

Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H (2002) Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 118(5):693–698. doi:10.1309/6ANB-QXCF-EHKC-7UC7 PubMedCrossRef

25.

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe 8(3):138–140PubMed

26.

Ryan SD, Britigan EM, Zasadil LM, Witte K, Audhya A, Roopra A, Weaver BA (2012) Up-regulation of the mitotic checkpoint component Mad1 causes chromosomal instability and resistance to microtubule poisons. Proc Natl Acad Sci USA 109(33):E2205–E2214. doi:10.1073/pnas.1201911109 PubMedCrossRef

27.

Chun AC, Jin DY (2003) Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J Biol Chem 278(39):37439–37450. doi:10.1074/jbc.M307185200 PubMedCrossRef

28.

Iwanaga Y, Jeang KT (2002) Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant. Cancer Res 62(9):2618–2624PubMed

29.

Kienitz A, Vogel C, Morales I, Muller R, Bastians H (2005) Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 24(26):4301–4310. doi:10.1038/sj.onc.1208589 PubMedCrossRef

30.

Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE, Mueller W (2003) Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer–association with tumour cell proliferation. J Pathol 200(1):16–22. doi:10.1002/path.1324 PubMedCrossRef

31.

Cheung HW, Jin DY, Ling MT, Wong YC, Wang Q, Tsao SW, Wang X (2005) Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 65(4):1450–1458. doi:10.1158/0008-5472.CAN-04-0567 PubMedCrossRef

Title: Increased expression of Mitotic Arrest Deficient-Like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer
Authors: Qian Sun
Xianyu Zhang
Tong Liu
Xiaolong Liu
Jingshu Geng
Xiaohui He
Yang Liu
Da Pang
Publication date: 01-07-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2633-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Tumour diploidy and survival in breast cancer patients with BRCA2 mutations

Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy

Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

The associations between a polygenic score, reproductive and menstrual risk factors and breast cancer risk

A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer